Bismuth-norfloxacin complex: Synthesis, physicochemical and antimicrobial evaluation

International Journal of Pharmaceutics

Volumn 332, Issue 1-2, 2007, Pages 24-30

  Shaikh, Anwar R ^a   Giridhar, Rajani ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Antibacterial activity; Bismuth norfloxacin complex; Norfloxacin

Indexed keywords

BISMUTH CITRATE; BISMUTH NORFLOXACIN COMPLEX; NORFLOXACIN; UNCLASSIFIED DRUG;

AGAR GEL DIFFUSION; ANTIMICROBIAL ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BACILLUS PUMILUS; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; INFRARED SPECTROSCOPY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; THERMOGRAVIMETRY; TITRIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY; WATER CONTENT;

ANTI-BACTERIAL AGENTS; BACILLUS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMBINATIONS; ESCHERICHIA COLI; HYDROGEN-ION CONCENTRATION; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NORFLOXACIN; ORGANOMETALLIC COMPOUNDS; SOLUBILITY; SPECTROPHOTOMETRY, ATOMIC; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TEMPERATURE; THERMOGRAVIMETRY; TITRIMETRY;

EID: 33846893875     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.037     Document Type: Article

References (27)

1. Aldrich Catalogue, 2001. p. 211.
2. Bland M.V., Salim I., Heinemann J.A., and Keenan J.I. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation. Antimicrob. Agents Chemother. 48 (2004) 1983-1988
3. Bolton S., and Bon C. Pharmaceutical Statistics, Practical and Clinical Applications (2001), Marcel Decker, Inc., New York pp. 215-264
4. Borrel J.H., and Montero M.T. Calculating microspecies concentration of zwitterion amphoteric compounds: ciprofloxacin as example. Chem. Educ. 47 (1997) 1311-1314
5. Bukovec P., Turel I., and Quirós M. Crystal structure of ciprofloxacin hexahydrate and its characterization. Int. J. Pharm. 152 (1997) 59-65
6. Clitherow, J., 1991. Salts of ranitidine and complexes of bismuth with carboxylic acids, and pharmaceutical compositions thereof. US Patent Number 5,008,256.
7. Domenico P., Reich J., and Madonia W. Resistance to bismuth among Gram-negative bacteria is dependent upon iron and its uptake. Antimicrob. Agents Chemother. 38 (1996) 1031-1040
8. Furet Y., Deshusses X., and Pechére J. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob. Agents Chemother. 36 (1992) 2506-2511
9. Gao F., Yang P., Xie J., and Wang H. Synthesis, characterization and antibacterial activity of novel Fe(III), Co(II), and Zn(II) complexes with norfloxacin. J. Inorg. Biochem. 60 (1995) 61-67
10. Indian Pharmacopoeia, 1996. Microbiological Assay of Antibiotics, 3rd ed. Published by Controller of Publications, Government of India, A-144.
11. Kawai Y.K., and Matsubayashi H. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Chem. Pharm. Bull. 44 (1996) 1425-1430
12. Leban I., Turel I., and Bukovec N. Crystal structure and characterization of the bismuth (III) compound with quinolone family member (ciprofloxacin). Antibacterial study. J. Inorg. Biochem. 66 (1997) 241-245
13. Ma H.H., Chiu F.C., and Li R.C. Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations. Pharm. Res. 14 (1997) 366-370
14. National Committee for Clinical Laboratory Standards, 1993. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 3rd ed. Approved Standard. NCCLS Document M11-A3, National Committee for Clinical Laboratory Standards, Wayne, PA, p. 13, 26.
15. Naumann P., and Dopp C. Fluoroquinolones-antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs. Internist (Berl.) 30 (1989) 20-31
16. Peter B., and Colm O.M. Treatment of Helicobacter pylori. Helicobacter 10 (2005) 40-46
17. In: Reynolds J.E. (Ed). Martindale, The Extra Pharmacopeia. 30th ed. (1993), Pharmaceutical Press, London 145-147
18. Sharma J., Singla A.K., and Dhawan S. Zinc-naproxem complex: physicochemical and biological evaluation. Int. J. Pharm. 260 (2003) 217-227
19. Shen L.L., and Pernet A.G. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc. Natl. Acad. Sci. 82 (1985) 307-311
20. Shen L.L. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J. Biol. Chem. 264 (1989) 2973
21. Shen L.L., Mitscher L.A., and Sharma P.N. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28 (1989) 3886-3894
22. Takahata M., and Nishino T. DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity. Antimicrob. Agents Chemother. 32 (1988) 1192
23. Turel I., Gruber K., Leban I., and Bukovec N. Synthesis, crystal structure, and characterization of three novel compounds of the quinolone family member (norfloxacin). J. Inorg. Biochem. 61 (1996) 197-212
24. Turel I., Leban I., and Bukovec N. Synthesis, characterization, and crystal structure of a copper (II) complex with quinolone family member (ciprofloxacin): bis(1)-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylate) copper (II) chloride hexahydrate. J. Inorg. Biochem. 56 (1994) 273-282
25. United States Pharmacopoeia 25 and National Formulary 20, 2002. Microbiological Tests. United States Pharmacopoeia Convention, Inc., pp. 1883-1889.
26. Willard H.H., Merritt L.L., and Settle J.A. Instrumental Methods of Analysis. 6th ed. (1986), EBS Publishers, Delhi by arrangement with Wadsworth, USA pp. 611-613
27. 2O. Crotica Chemica Acta 74 (2001) 61-74